Overview of Dr. Donovan
Dr. Laura Donovan is a neurologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and James J. Peters Veterans Affairs Medical Center. She received her medical degree from Emory University School of Medicine and has been in practice 5 years. She is one of 483 doctors at New York-Presbyterian Hospital and one of 211 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Neurology. She has more than 10 publications and over 200 citings.
Office
710 West 168th Street
New York, NY 10032
Education & Training
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 2013 - 2016
Brown UniversityResidency, Internal Medicine, 2012 - 2013
Emory University School of MedicineClass of 2012
Certifications & Licensure
FL State Medical License 2021 - Present
CT State Medical License 2021 - 2025
NJ State Medical License 2022 - 2025
NY State Medical License 2016 - 2025
RI State Medical License 2012 - 2013- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 3 citationsHealth related quality of life trajectories after stereotactic radiosurgery for brain metastases: a systematic review.Adomas Bunevicius, Laura Donovan, Jason Sheehan
Journal of Neuro-Oncology. 2022-09-01 - 2 citationsCauses of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study.Marissa Barbaro, Craig D. Blinderman, Fabio M. Iwamoto, Teri N. Kreisl, Mary Welch
Neurology. 2021-11-18 - Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.Laura E. Donovan, Eric B. Dammer, Duc M. Duong, John Hanfelt, Allan I. Levey
Alzheimer's Research & Therapy. 2021-05-18
Lectures
- Hyperprogressive disease in patients with recurrent high grade gliomas treated with immune checkpoint inhibitors or other therapies.2019 ASCO Annual Meeting - 6/1/2019
- A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Karen Killilea, 80, Dies; Turned Disability into TriumphDecember 18th, 2020- Researchers Report Promising New Therapy for Recurrent Pediatric Brain CancersMay 1st, 2020
CAR T Therapy Helps Treat Pediatric Brain TumorsApril 28th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
